Publications by authors named "Michiko Togane"
Introduction: This study investigated the relationships between changes in renal prognosis-related factors after initiating tofogliflozin and the corresponding baseline values in clinical practice in Japanese patients with type 2 diabetes.
Methods: We investigated the relationships between changes in hematocrit, hemoglobin, systolic blood pressure (sBP), urinary protein excretion (uPE), serum uric acid (sUA), and estimated glomerular filtration rate (eGFR) 12 months after initiating tofogliflozin (20 mg) and their corresponding baseline values in 130 patients with type 2 diabetes. The subjects were divided into two groups: normal (≥60 mL/min/1.
Article Synopsis
- The study examined the effectiveness of a combination therapy of insulin degludec and liraglutide (IDegLira) in managing type 2 diabetes among Japanese patients, particularly focusing on liver health as assessed by the Fibrosis-4 index (FIB-4).
- In a group of 113 patients over 6 months, both those previously treated with glucagon-like peptide-1 receptor agonists (GLP-1RA) and those who were not showed significant reductions in glycated hemoglobin, indicating improved blood sugar control.
- While weight decreased in the GLP-1RA-naïve group, it slightly increased in the GLP-1RA-treated group, and FIB-4 levels improved
Aim: The incidence of cardiovascular and renal events was investigated in patients with type 2 diabetes who were classified according to anemia and the components of dialysis-independent chronic kidney disease (CKD) in a prospective observational study.
Methods: A population of 778 Japanese patients with type 2 diabetes was prospectively analyzed for 4 years. The outcomes were the incidence of cardiovascular events and renal events.
Article Synopsis
- A study evaluated the effect of tofogliflozin, an SGLT2 inhibitor, on glomerular filtration rate (eGFR) in Japanese type 2 diabetes patients with renal issues over 12 months.
- 158 patients were analyzed, with a focus on those who continued treatment for the entire year, revealing various health improvements such as weight loss and blood pressure reduction among both normal and low eGFR groups.
- The findings suggest that tofogliflozin helps maintain renal function over the medium term without increasing the risk of adverse effects.
Introduction The dose of roxadustat, a hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor, required to treat anemia, the hemoglobin level and the rate of hemoglobin target achievement were retrospectively investigated in non-dialyzed chronic kidney disease (CKD) patients with and without type 2 diabetes. Methods As the full analysis set, 25 subjects (10 with diabetes and 15 without diabetes) were observed over six months among 44 non-dialyzed CKD patients who received roxadustat. The target hemoglobin level was set at 110-130 g/L.
View Article and Find Full Text PDFObjective Diabetes is recognized as an underlying disease of constipation. However, the prevalence of constipation varies according to the diagnostic criteria applied. We investigated the prevalence of constipation based on the new guideline for constipation in Japanese patients with type 2 diabetes and examined the relationship with the clinical background, including diabetic vascular complications.
View Article and Find Full Text PDFArticle Synopsis
- The study evaluated how effective dulaglutide is for managing type 2 diabetes, taking into account different treatment backgrounds before starting dulaglutide.
- 89 patients were categorized into three groups based on their prior treatments: additional therapy, switching from DPP-4 inhibitors, and switching from daily GLP-1 receptor agonists.
- Results showed that HbA1c levels significantly decreased in all groups, with improved medication adherence noted among those who previously took daily GLP-1 RAs, suggesting that dulaglutide is effective regardless of previous treatments.
Aims: The safety and efficacy, particularly, the factors associated with the renal prognosis, were assessed over 12 months after the initiation of luseogliflozin therapy in Japanese patients with type 2 diabetes and renal impairment.
Methods: In total, 238 patients treated with luseogliflozin (2.5 mg, once daily) were studied as the safety analysis set.
Article Synopsis
- A study was conducted on 675 Japanese patients with type 2 diabetes to evaluate their renal and cardiovascular health over 4 years, specifically focusing on those with reduced eGFR without albuminuria.
- Results showed unchanged eGFR levels in non-albuminuric patients, whereas those with albuminuria experienced a decline, and cardiovascular events occurred more frequently in patients with albuminuria.
- The findings emphasize that while non-albuminuric patients with reduced eGFR are at lower risk for kidney disease, they still face significant cardiovascular risks that should be monitored.
Purpose: The factors associated with the renal prognosis over six months after the initiation of empagliflozin were compared between the non-elderly and elderly Japanese patients with type 2 diabetes.
Patients And Methods: In total, 132 patients treated with empagliflozin (10 mg, once daily) were studied as the safety analysis set. One hundred ten subjects whose medications were not changed during the observation period were investigated as the full analysis set to assess the effectiveness.
Article Synopsis
- The study aimed to assess how switching from daily DPP-4 inhibitors to weekly trelagliptin affects patient satisfaction, medication adherence, and unused medication in type 2 diabetes patients.
- A total of 79 patients participated after excluding those who didn't want to switch; their satisfaction and adherence were measured at baseline and 3 months post-switch.
- Results showed no change in HbA1c levels, but significant improvements in treatment satisfaction, perception of medication, adherence, and a reduction in unused drugs after the switch.
Article Synopsis
- - The study compared the effects of switching type 2 diabetes patients from insulin glargine U100 to either an IGlar biosimilar or IGlar U300 over six months, focusing on changes in HbA1c levels and body weight.
- - Results showed no significant differences in HbA1c levels or body weight between the two groups, with IGlar U300 users experiencing a notable decrease in hypoglycemia occurrences compared to before the switch.
- - Overall, both IGlar biosimilar and IGlar U300 produced similar outcomes in managing diabetes, suggesting that IGlar biosimilar is a good option, especially for patients who are less prone to hypoglycemia.
Article Synopsis
- A study examined the link between cognitive function and clinical aspects of chronic kidney disease (CKD) in Japanese patients without overt dementia.
- Out of 497 patients initially screened, 191 were analyzed, revealing average cognitive scores (MMSE) and correlations with age and kidney function, particularly noting that older patients (≥70 years) had lower scores.
- Findings suggest cognitive function is affected in CKD patients even without dementia, emphasizing the need for early interventions to safeguard cognitive and kidney health.
Article Synopsis
- The study investigated the link between urinary liver-type fatty acid-binding protein (L-FABP) levels and clinical characteristics of type 2 diabetes patients, particularly focusing on those with normal vs. elevated albumin levels.
- Urinary L-FABP was measured in 788 participants, revealing that high levels were significantly associated with factors like HbA1c, blood pressure, and renal function in normoalbuminuric patients, while specific medications and urinary albumin levels affected albuminuric patients.
- The findings suggest that elevated urinary L-FABP relates to metabolic issues such as high HbA1c and blood pressure, indicating it could be a valuable biomarker for assessing kidney health in diabetes patients.
Objective The effects of febuxostat therapy on hyperuricemia in patients with and without type 2 diabetes were compared in this retrospective observational study after pair-matching using the propensity scores. Methods In total, 160 patients with hyperuricemia were studied as the treated set, and the 155 subjects in whom the administration of febuxostat was not discontinued during the observation period were investigated in the full analysis. The study subjects were divided into two groups based on the style of initiation of febuxostat: initial and switching therapy from allopurinol administration.
View Article and Find Full Text PDFArticle Synopsis
- - The study explored changes in clinical characteristics and medication prescriptions among type 2 diabetic patients experiencing severe hypoglycemia from 2008 to 2013, revealing significant shifts in medication types used.
- - An increase in patients using insulin, biguanides, and other newer medications was noted, while the use of sulfonylureas dropped significantly. Additionally, the frequency of medication errors contributing to hypoglycemia rose over the same period.
- - The findings highlight a rise in polypharmacy among insulin users and emphasize the need for effective education on medication management to prevent severe hypoglycemia in these patients.
Article Synopsis
- - The study aimed to explore how the duration of type 2 diabetes impacts the health status of elderly patients (aged 65 and older) compared to younger patients.
- - Results showed that longer diabetes duration was linked to higher insulin use and worse blood sugar control, with increased risks for conditions like diabetic retinopathy, nephropathy, and neuropathy in both age groups, but not for diseases like coronary heart disease in elderly patients.
- - The findings suggest that while diabetes duration affects microvascular complications, atherosclerotic diseases must be considered for effective management of elderly patients, regardless of how long they have had diabetes.
We aimed to clarify the usefulness of measuring the flow mediated dilatation (FMD) in patients with type 2 diabetes mellitus without and with coronary heart disease (CHD). The FMD was measured in 480 patients with type 2 diabetes and in 240 nondiabetic subjects. The FMD was significantly lower in the subjects with CHD (n = 145, 5.
View Article and Find Full Text PDFArticle Synopsis
- The study aimed to examine the impact of linagliptin (a diabetes medication) on patients with type 2 diabetes over six months, focusing on their kidney function.
- Two hundred sixteen Japanese patients were observed, divided into three groups based on their estimated glomerular filtration rate (eGFR), to assess linagliptin's effectiveness.
- Results showed significant HbA1c level improvements in all groups, indicating that linagliptin is effective for managing diabetes even in patients with impaired kidney function.
Background: The effects of switching from prandial premixed insulin therapy (PPT) injected three times a day to basal plus two times bolus insulin therapy (B2B) on glycemic control and quality of life were investigated in patients with type 2 diabetes mellitus.
Methods: The clinical course was prospectively observed during the first 16 weeks after switching to B2B (insulin glargine plus insulin glulisine before breakfast and dinner) in 27 subjects previously treated with PPT using 50/50 premixed insulin. The Diabetes Treatment Satisfaction Questionnaire (DTSQ) was administered at the start and end of the study.
Background/aims: The prevalence of the risk factors for atherosclerosis, other than diabetes mellitus, among type 2 diabetic patients with different stages of chronic kidney disease (CKD) determined by glomerular filtration rate (GFR) was investigated.
Methods: The prevalence of ten risk factors (age ≥65 years, history of smoking, male gender, obesity, albuminuria, hypertension, hypercholesterolemia, hypo-HDL-cholesterolemia, hyperuricemia and anemia) was determined in 2,107 Japanese type 2 diabetic patients with different stages of CKD (six stages according to GFR).
Results: The risk factors for age ≥65 years and male gender were found in 49 and 62% of the study subjects, respectively.
Introduction: Vildagliptin can be used in patients with type 2 diabetes mellitus and renal impairment. However, there have been few reports investigating the clinical effectiveness of vildagliptin in diabetic patients undergoing hemodialysis. No previous studies have evaluated the use of vildagliptin in patients undergoing peritoneal dialysis.
View Article and Find Full Text PDFBackground: The relationship between hypoglycemia and the dose of insulin used in patients with type 2 diabetes mellitus was investigated by continuous glucose monitoring (CGM).
Patients And Methods: In total, 83 CGM studies were performed in 70 outpatients with type 2 diabetes receiving treatment by subcutaneous insulin injection.
Results: The total dose of insulin, bolus insulin dose, and basal insulin dose used in the subjects were 32±18 units, 19±13 units, and 13±8 units, respectively.
Objective: To clarify the clinical characteristics of type 2 diabetic patients with non-alcoholic fatty liver disease (NAFLD) and to assess whether NAFLD is related to angiopathy.
Methods: The study included 388 Japanese type 2 diabetic outpatients without viral hepatitis. The main outcome measures were angiopathy and NAFLD.
Background: We investigated 1) the frequency of hypertension in patients with type 2 diabetes graded by the new classification of chronic kidney disease (CKD) reported by the Kidney Disease: Improving Global Outcomes (KDIGO) and 2) the number of antihypertensive agents needed to achieve treatment goals using a prospective observational study.
Methods: A population of 2018 patients with type 2 diabetes mellitus was recruited for the study. The CKD stage was classified according to the eGFR and the urinary albumin excretion levels.